Cabaletta Bio, Inc. (NASDAQ:CABA) Receives Average Rating of "Moderate Buy" from Analysts

Key Points

• "Moderate Buy" consensus from seven analysts (six buys, one sell) with an average 12‑month price target of $17.00, though individual views diverge (targets and ratings range from sell to a $30 target).
• Shares trade around $4.00 (52‑week range $1.11–$4.23) with a market cap near $445 million; the company reported a quarterly EPS of -$0.40 (beating estimates) and analysts expect about -1.5 EPS for the year.
• Cabaletta is a clinical‑stage biotech developing CAAR‑T therapies, with lead candidate DSG3‑CAART targeting pemphigus vulgaris.

Shares of Cabaletta Bio, Inc. (NASDAQ:CABA - Get Free Report) have earned an average rating of "Moderate Buy" from the seven analysts that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $17.00.

A number of research analysts recently weighed in on the company. Guggenheim lifted their target price on Cabaletta Bio from $15.00 to $16.00 and gave the company a "buy" rating in a report on Tuesday, March 24th. Weiss Ratings restated a "sell (d-)" rating on shares of Cabaletta Bio in a research note on Monday, April 20th. Morgan Stanley reduced their price objective on Cabaletta Bio from $14.00 to $13.00 and set an "overweight" rating on the stock in a research note on Tuesday, March 24th. Wall Street Zen cut Cabaletta Bio from a "hold" rating to a "sell" rating in a report on Saturday, April 18th. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $30.00 target price on shares of Cabaletta Bio in a research report on Monday.

Institutional Trading of Cabaletta Bio

A number of institutional investors have recently added to or reduced their stakes in CABA. Kestra Advisory Services LLC acquired a new stake in shares of Cabaletta Bio in the first quarter valued at about $32,000. China Universal Asset Management Co. Ltd. purchased a new position in Cabaletta Bio in the 4th quarter worth approximately $34,000. ANTIPODES PARTNERS Ltd acquired a new stake in Cabaletta Bio in the fourth quarter valued at approximately $38,000. Private Advisor Group LLC grew its position in Cabaletta Bio by 22.4% in the first quarter. Private Advisor Group LLC now owns 18,025 shares of the company's stock valued at $48,000 after acquiring an additional 3,300 shares in the last quarter. Finally, Clear Harbor Asset Management LLC purchased a new stake in shares of Cabaletta Bio during the fourth quarter valued at approximately $43,000.

Cabaletta Bio Stock Up 7.2%

Shares of Cabaletta Bio stock opened at $4.00 on Friday. Cabaletta Bio has a fifty-two week low of $1.11 and a fifty-two week high of $4.23. The firm has a market cap of $445.28 million, a PE ratio of -1.75 and a beta of 3.18. The business's fifty day moving average is $3.14 and its two-hundred day moving average is $2.72.

Cabaletta Bio (NASDAQ:CABA - Get Free Report) last announced its quarterly earnings data on Monday, March 23rd. The company reported ($0.40) EPS for the quarter, beating analysts' consensus estimates of ($0.45) by $0.05. Equities research analysts anticipate that Cabaletta Bio will post -1.5 EPS for the current year.

Cabaletta Bio Company Profile

Cabaletta Bio is a clinical-stage biotechnology company pioneering chimeric autoantibody receptor T cell (CAAR-T) therapies for B cell–mediated autoimmune diseases. Its proprietary platform engineers patient-derived T cells to selectively target and eliminate pathogenic B cells that produce disease-driving autoantibodies, with the aim of preserving overall immune function and reducing off-target toxicity.

The company's lead candidate, DSG3-CAART, is being evaluated in pemphigus vulgaris, a rare blistering disorder caused by autoantibodies against desmoglein 3.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.